145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775)
Makaleler > Tam Makale · 2021
Yazarlar: N. Colombo, D. Lorusso, A.D. Santin, Y.M. Kim, A.C. Herráez, K. Yonemori, K. Fujiwara, E. Colomba, D.S. Miller, S. Pignata, B.J. Monk, E.M. Guerra, R. Kristeleit, M. Orlando, U.A. Sanli, L. Dutta, R. Orlowski, M. Ren, V. Makker
International Journal of Gynecological Cancer, Uluslararası, Wos, 2021, cilt 31, ss A78-A78